Conmana
(Icotinib)Phase 3Small molecule
Icotinib is used to treat a specific type of lung cancer called non-small cell lung cancer in patients whose cancer cells have certain mutations in a gene called EGFR.[1] Conmana is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Conmana is one of 121 small molecule programs targeting Adjuvant Therapy. It is currently in Phase 3.
5
Indications
64
Total Trials
6
Active Trials
120
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Conmana
BBetta Pharmaceuticals Co., Ltd.
Phase 3
Leqembi
EisaiPhase 3
Krazati
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Oleclumab
AstraZenecaPhase 3
Remeron
OOrganon and Co
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer14 trials
Show 11 more trials
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
Unknown status·PPeople's Hospital of Guangxi Zhuang Autonomous Region·Phase 2·NCT02407366·80 enrolled
Lung Cancer9 trials
Show 6 more trials
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Unknown status·—·Phase 2·NCT01963195·30 enrolled
Lung Adenocarcinoma5 trials
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
Unknown status·—·Phase 4·NCT02283424·10 enrolled
EGFR Mutation3 trials
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Unknown status·—·Phase 2·NCT02820116·67 enrolled
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Unknown status·—·Phase 3·NCT02883543·330 enrolled
First-line Treatment2 trials
23 more indications
Pancreatic Cancer2 trials
Brain Metastases2 trials
Adjuvant Therapy2 trials
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT06955325·270 enrolled
Small Cell Lung Cancer2 trials
Advanced NSCLC2 trials
Adenocarcinoma2 trials
Chemotherapy2 trials
Nasopharyngeal Carcinoma2 trials
Esophageal Cancer1 trial
Non-squamous NSCLC1 trial
Prospective1 trial
Radiation Therapy1 trial
Real-world Study1 trial
Growth1 trial
Triple-Negative Breast Cancer1 trial
Esophageal Carcinoma1 trial
Neurofibromatosis1 trial
Metastasis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Icotinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Epidermal Growth Factor Receptor Erbb1 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBetta Pharmaceuticals Co., Ltd.